Source Chain Tech Stock Could Get a ‘Shot in the Arm’ From the COVID Vaccine Rollout

Tecsys Inc. (TSX:TCS) has the likely to dominate the $600 million healthcare source chain management room

Money Concepts Media | February 5, 2021 | SmallCapPower: Provide chain management, which makes certain the efficient movement of products setting up from gathering the raw resources all the way to shipping of the ultimate product or service, has become essential in our more and more advanced international industrial ecosystem.

(Originally posted on Capital Strategies Media on December 15, 2020)

 

Canadian enterprise Tecsys Inc. (TSX:TCS) develops and sells company-broad source chain administration software program for distribution, warehousing, and transportation logistics, focusing on principally the North American current market.

[Editor’s Note: Shares of Tecsys have climbed 19% since Capital Ideas wrote about the company about six weeks ago.]

[Please click here to get immediate access to curated research in the weekly Capital Ideas Digest with our free 30-Day Trial.] 

The business just lately documented improved-than-predicted Q2 Fiscal 2021 revenue that rose 18% year around year to $30.7 million, its seventh consecutive quarterly major-line file. About 63% of its product sales through the earlier 12 months came from the United States and Tecsys has more than 1000 customers worldwide.

Recurring profits, while, carries on to be the focus at Tecsys, as its yearly recurring earnings climbed 26% 12 months around year to $50.9 million, which it attributed mostly to eCommerce proliferation.

As properly, bigger-margin SaaS (computer software as a support) earnings proceeds to be the Company’s quickest-developing profits stream (now accounting for 17% of gross sales), with trailing twelve thirty day period SaaS bookings surging 159% from a calendar year earlier. The Company’s changeover to a SaaS small business product is anticipated to drive accelerated organic and natural expansion.

Tecsys also recorded a next-quarter revenue of $2.1 million or $.14 per share, up from $1.4 million, or $.11 per share, through the exact same time period very last 12 months.

Cormark Securities analyst Gavin Fairweather wrote lately that Tecsys is possessing conversations on possible opportunities to provide application to control the distribution of COVID-19 vaccines.

“Its answer is compliant with drug offer chain protection act prerequisites and can manage cold chain deployments. The R&D workforce has also formulated a position-of-use software to monitor the supply of the vaccine,” he explained, incorporating that prospective income from this could be “meaningful.”

Tecsys does have encounter in this place, suggests Laurentian Financial institution Securities analyst Nick Agostino, who mentioned that the Organization was involved in the H1N1 vaccine rollout in the US over a interval of about a calendar year in 2009.

Mr. Agostino mentioned that Tecsys proceeds to discover M&A possibilities inside the US health care source chain management room, as nicely as “expanding its geographical get to in Europe and Asia to complement natural and organic advancement.” The global healthcare source chain management sector is estimated to be a $600 million sector chance.

Lastly, Tecsys traders have benefitted from the Company’s restricted capital structure (just 14.4 million shares fantastic), about 26% of which are owned by Company insiders.

To read our comprehensive disclosure, remember to simply click on the button below:

The Information contained on this web page (like any details, sights, opinions, recommendations, description of, or references to, merchandise or securities) made available by SmallCapPower/Ubika Investigate is for information reasons only and is not customized to the wants or conditions of any individual particular person. Any point out of a particular protection is just a common dialogue of the deserves and pitfalls related there with and is not to be utilised or construed as an supply to market, a solicitation of an offer to obtain, or an endorsement, suggestion, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should really apply his/her possess judgment in creating any use of any Information, which include, without limitation, the use of any info contained therein as the foundation for any conclusions. The Reader bears duty for his/her very own investment investigate and choices. Right before producing any investment decision selection, it is strongly advisable that you find outside suggestions from a skilled investment decision advisor. SmallCapPower/Ubika Investigate does not deliver or assurance any financial, legal, tax, or accounting suggestions or guidance pertaining to the suitability, profitability, or probable price of any particular investment decision, security, or facts resource. Ubika and/or its affiliates and/or their respective officers, directors or workers may perhaps from time to time acquire, keep or provide securities and/or commodities and/or commodity futures contracts in specified fundamental providers stated in this website and which may well also be clientele of Ubika’s affiliate marketers. In these circumstances, Ubika and/or its affiliates and/or their respective officers, administrators or staff members will use all reasonable initiatives to avoid participating in actions that would guide to conflicts of interest and Ubika and/or its affiliate marketers will use all realistic initiatives to comply with conflicts of curiosity disclosures and polices to limit the conflict.